Nivolumab (Opdivo) - Oncology Nurse Advisor

Nivolumab (Opdivo)

Slideshow

  • Opdivo (rev 8/17) slide 1

  • Opdivo (rev 8/17) slide 2

  • Opdivo (rev 8/17) slide 3

  • Opdivo (rev 8/17) slide 4

  • Opdivo (rev 8/17) slide 5

  • Opdivo (rev 8/17) slide 6

  • Opdivo (rev 8/17) slide 7

  • Opdivo (rev 8/17) slide 8

  • Opdivo (rev 8/17) slide 9

  • Opdivo (rev 8/17) slide 10

  • Opdivo (rev 8/17) slide 11

  • Opdivo (rev 8/17) slide 12

  • Opdivo (rev 8/17) slide 13

  • Opdivo (rev 8/17) slide 14

  • Opdivo (rev 8/17) slide 15

  • Opdivo (rev 8/17) slide 16

  • Opdivo (rev 8/17) slide 17

  • Opdivo (rev 8/17) slide 18

  • Opdivo (rev 8/17) slide 19

  • Opdivo (rev 8/17) slide 20

  • Opdivo (rev 8/17) slide 21

  • Opdivo (rev 8/17) slide 22

  • Opdivo (rev 8/17) slide 23

  • Opdivo (rev 8/17) slide 24

  • Opdivo (rev 8/17) slide 25

  • Opdivo (rev 8/17) slide 26

  • Opdivo (rev 8/17) slide 27

  • Opdivo (rev 8/17) slide 28

  • Opdivo (rev 8/17) slide 29

  • Opdivo (rev 8/17) slide 30

  • Opdivo (rev 8/17) slide 31

  • Opdivo (rev 8/17) slide 32

  • Opdivo (rev 8/17) slide 33

  • Opdivo (rev 8/17) slide 34

  • Opdivo (rev 8/17) slide 35

  • Opdivo (rev 8/17) slide 36

  • Opdivo (rev 8/17) slide 37

This slideshow examines nivolumab (Opdivo), indicated for the treatment of patients with Metastatic non-small cell lung cancer, advanced renal cell carcinoma, and classical Hodgkin lymphoma.

Table of Contents

Slide 5: Dosage and Administration
Slide 15: Cautions, Effects, and Interactions
Slide 26: What to Tell Your Patient
Slide 35: Reference

Next hm-slideshow in Slides